RxDoctor Payments Data

Aldo Schenone, MD

Internal Medicine · Cleveland, OHNPI 1659634160

Payments from drug & device makers

$17,183in general payments, 2019–2025

Across 69 payments — averaging $249.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$16K
  • Bristol Myers Squibb$408
  • Novartis$273
  • Eli Lilly$211
  • Heartflow, Inc.$149
  • AstraZeneca$110
  • plus $146 from 3 others

What the payments were for

  • Consulting fees$1,5009%
  • Speaking & faculty fees$13,55080%
  • Food & beverage$1,92211%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,183 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$93,672
Medicare patients
589
Services billed
1,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten49$410,515
EntrestoSacubitril/Valsartan234$263,039
FarxigaDapagliflozin Propanediol207$188,163
EliquisApixaban124$138,269
JardianceEmpagliflozin98$108,947
Repatha SureclickEvolocumab97$100,733
OzempicSemaglutide35$37,097
VascepaIcosapent Ethyl47$23,663
Praluent PenAlirocumab27$22,490
Repatha SyringeEvolocumab19$20,182
BrilintaTicagrelor16$16,539
XareltoRivaroxaban12$12,366
Atorvastatin Calcium557$6,586
Metoprolol Succinate309$4,544
Colchicine53$4,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$15,886$410,51549 claims
NovartisEntresto$273$263,039234 claims
AstraZenecaFarxiga, Brilinta$110$204,702223 claims
PfizerEliquis$96$138,269124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →